Amgen Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 5, 2026, covering the fiscal quarter ended June 30, 2026, and disclosing condensed consolidated financial statements for that period.

Key Highlights

  • Total revenues: $10,054 million for Q2 2026, up from $9,179 million in Q2 2025, according to the filing.
  • Product sales: $9,537 million for the three months ended June 30, 2026, compared with $8,771 million for the same period in 2025.
  • Net income: $2,375 million for Q2 2026, versus $1,432 million in Q2 2025, as reported in the filing.
  • Diluted EPS: $4.37 for the second quarter of 2026, compared with $2.65 for the second quarter of 2025.
  • Six-month net income: $4,194 million for the first half of 2026, versus $3,162 million for the first half of 2025.
  • Shares outstanding: 540,632,005 shares of common stock as of July 30, 2026, per the filing.

Amgen's Second-Quarter 2026 Revenue and Earnings Results

According to the filing, Amgen Inc. (The Nasdaq Global Select Market: AMGN) reported total revenues of $10,054 million for the three months ended June 30, 2026, compared with $9,179 million for the same quarter in 2025. Product sales accounted for $9,537 million of Q2 2026 revenues, with other revenues contributing $517 million. For the six-month period ended June 30, 2026, the company reported total revenues of $18,672 million, up from $17,328 million in the first half of 2025.

The filing disclosed total operating expenses of $6,540 million for Q2 2026, compared with $6,523 million in Q2 2025. Research and development expenses were $1,868 million in Q2 2026, versus $1,744 million in Q2 2025. Cost of sales decreased to $2,811 million in Q2 2026 from $3,011 million in Q2 2025. Operating income for the quarter was $3,514 million, compared with $2,656 million in the prior-year quarter. Net interest expense was $(673) million for Q2 2026, versus $(694) million for Q2 2025.

The registrant reported basic earnings per share of $4.40 and diluted earnings per share of $4.37 for Q2 2026, based on weighted-average diluted shares of 544 million. For the six months ended June 30, 2026, the filing disclosed net income of $4,194 million, diluted EPS of $7.71, and comprehensive income of $4,333 million. The provision for income taxes was $393 million for Q2 2026, compared with $136 million for Q2 2025.

What Was Disclosed

Amgen's 10-Q for the quarter ended June 30, 2026, disclosed condensed consolidated income statements, comprehensive income, balance sheets, and cash flows, along with management's discussion, risk factors, and legal proceedings updates for the period.